



AtriCure to Present at the 35th Annual JP Morgan Healthcare Conference

December 15, 2016

MASON, Ohio--(BUSINESS WIRE)--Dec. 15, 2016-- [AtriCure, Inc. \(Nasdaq:ATRC\)](#), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announced that it will present at the 35th Annual JP Morgan Healthcare Conference at the Westin St. Francis Hotel in San Francisco on Thursday, January 12, 2017. Management is scheduled to present at 9:30 a.m. Pacific Time. A live audio webcast of the presentation may be accessed by visiting the Investors page of AtriCure's corporate website at www.atricure.com. A replay of the presentation will be available for 90 days following the presentation.

About AtriCure

AtriCure, Inc. is a medical device company that provides innovative solutions designed to decrease the global Afib epidemic. AtriCure's Isolator® Synergy™ Ablation System is the first and only surgical device approved for the treatment of persistent and longstanding persistent forms of Afib in patients undergoing certain open concomitant procedures. AtriCure's AtriClip® Left Atrial Appendage Management (LAAM) exclusion device is the most widely sold device worldwide that is indicated for the occlusion of the left atrial appendage. AtriCure believes electrophysiologists and cardiothoracic surgeons are adopting its technologies for the treatment of Afib and reduction of Afib related complications. Afib affects more than 33 million people worldwide. For more information, visit AtriCure.com or follow us on Twitter [@AtriCure](#).

View source version on businesswire.com: <http://www.businesswire.com/news/home/20161215005297/en/>

Source: AtriCure, Inc.

AtriCure, Inc.

Andy Wade, 513-755-4564

Senior Vice President and Chief Financial Officer

awade@atricure.com

or

Gilmartin Group

Lynn Pieper Lewis, 415-937-5402

Investor Relations

lynn@gilmartinir.com